Background: The activities of the HS (sulfhydryl or thiolic) group in the cysteine of glutathione or various low-weight soluble molecules (thiolic drugs), such as N-acethylcysteine, mesna, thiopronine and dithiotreitol or stepronine and erdosteine (prodrugs), include its antioxidant activity in the airways during the release of reactive oxygen or nitrogen species (ROS, RNS) by polymorphonuclear neutrophils (PMNs) activated in response to exogenous or endogenous stimuli. Objective: In addition to being administered by means of thiolic molecules, the HS group can also be given by means of the inhalation of sulphurous thermal water. The aim of this study was to investigate the effect of sulphurous thermal water on the release of ROS and RNS during the bursts of human PMNs. Methods: The luminol-amplified chemiluminescence methodology was used to investigate the ROS and RNS released by PMNs stimulated with N-formyl-methionyl-leucyl-phenylalanine and phorbol-12-myristate-13-acetate, before and after incubation with sulphurous water. Effects on cell-free systems were also investigated. Results: The water significantly reduced the luminol-amplified chemiluminescence of N-formyl-methionyl-leucyl-phenylalanine- andphorbol-12-myristate-13-acetate-activated PMNs on average from 0.94 to 15.5 µg/ml of HS, even after the addition of L-arginine, a nitric oxide (NO) donor. Similar findings have also been obtained in a cell-free system, thus confirming the importance of the presence of the HS group (reductive activity). Conclusions: The positive effects of the activity of sulphurous thermal waters has been partially based on the patients’ subjective sense of wellbeing and partially on not always easy to quantify symptomatic (or general) clinical improvements. Our findings indicate that, in addition to their known mucolytic activity and trophic effects on respiratory mucosa, the HS groups present in the sulphurous thermal water of this spring also have antioxidant activity that contributes to the therapeutic effects of the water in upper and lower airway inflammatory diseases.

Keywords:
Sulphurous thermal water, HS group, Antioxidant activity, Polymorphonuclear neutrophils, Luminol-amplified chemiluminescence, Cell-free system
1.
Tao F, Gonzales-Flecha B, Kobzik L: Reactive oxygen species in pulmonary inflammation by ambient particulates. Free Rad Biol Med 2003;34:327–340.
2.
Bals R, Hiemstra PS: Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Resp J 2004;23:327–333.
3.
Cassatella MA: The production of cytokines by polymorphonuclear neutrophils. Immunol Today 1995;16:21–26.
4.
MacNee W: Oxidative stress and lung inflammation in airway disease. Eur J Pharmacol 2001;429:195–207.
5.
Rahman I: Oxidative stress, chromatin remodelling and gene transcription in inflammation and chronic lung diseases. J Biochem Mol Biol 2003;36:95–109.
6.
Rahman I, Biswas SK, Kode A: Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol 2006;533:222–229.
7.
Folkerts G, Klock J, Muijsers RBR, Nijkamp FP: Reactive nitrogen and oxygen species in airway inflammation. Eur J Pharmacol 2001;429:251–262.
8.
Chabot F, Mitchell JA, Gutteridge JM, Evans TW: Reactive oxygen species in acute lung injury. Eur Resp J 1998;11:745–757.
9.
MacNee W, Rahman I: Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease? Trends Molec Med 2001;7:55–62.
10.
Cross CE, Van der Vliet A, O’Neill CA, Louie S, Halliwell B: Oxidants, antioxidants and respiratory tract lining fluids. Env Health Perspect 1994;102:185–191.
11.
Cantin AM, North SL, Hubbard RC, Crystal RG: Normal alveolar epithelial lining fluid contains high levels of glutathione. J Appl Physiol 1987;63:152–157.
12.
Patterson CE, Rhoades RA: Protective role of sulphydryl reagents in oxidant lung injury. Exp Lung Res 1988;14:1005–1019.
13.
Heffner JE, Repine JE: Pulmonary strategies of antioxidant defense. Am Rev Respir Dis 1989;140:531–554.
14.
Meister A: Glutathione-ascorbic acid antioxidant system in animal. J Biol Chem 1994;269:9397–9400.
15.
Rahman I: Regulation of glutathione in inflammation and chronic lung diseases. Mutat Res 2005;579:58–80.
16.
Braga PC, Ziment I, Allegra L: Classification of agents that act on bronchial mucus; in Braga PC, Allegra L (eds): Drugs in Bronchial Mucology. New York, Raven Press, 1989, pp 59–67.
17.
Allegra L, Dal Sasso M, Bovio C, Massoni C, Fonti E, Braga PC: Human neutrophil oxidative bursts and their in vitro modulation by different N-acetylcysteine concentrations. Arzneim Forsch 2002;52:669–676.
18.
Braga PC, Dal Sasso M, Zuccotti T: Assessment of the antioxidant activity of the SH-metabolite I of erdosteine on human neutrophil oxidative bursts. Arzneim Forsch 2000;50:739–746.
19.
Radi R, Cosgrove TP, Beckman JS, Freeman BA: Peroxynitrite-induced luminol chemiluminescence. Biochem J 1993;290:51–57.
20.
Allen RC: Phagocytic oxygenation activities and chemiluminescence: a kinetic approach to analysis. Methods Enzymol 1986;133:449–493.
21.
Merenyi G, Lind J, Eriksen TE: Luminolchemiluminescence: chemistry, excitation, emitter. J Biolum Chemilum 1990;5:53–56.
22.
Briheim G, Dahlgren C: Influence of antibiotics on formylmethionyl-leucyl-phenylalanine-induced leukocyte chemiluminescence. Antimicrob Agents Chemother 1987;31:763–769.
23.
American Public Health Association: Standard Methods for the Examination of the Water and Wastewater, ed 20. Washington, American Public Health Association, pp 4–167.
24.
Van Dyke K, McConnell P, Marquardt L: Green tea extract and its polyphenols markedly inhibit luminol-dependent chemiluminescence activated by peroxynitrite or SIN-1. Luminescence 2000;15:37–43.
25.
Radi R, Beckman JS, Bush KM: Peroxynitrite oxidation of sulphydryls. The cytotoxic potentials of superoxide and nitric oxide. J Biol Chem 1991;266:4244–4250.
26.
Ginsburg I, Sadovnic M, Oron M, Kohen R: Novel chemiluminescence-inducing cocktails. I. The role of light emission of combinations of luminol with SIN-1, selenite, albumin, glucose oxidase and Co2+. Immunopharmacology 2004;12:289–303.
27.
Ginsburg I, Sadovnic M, Oron M, Kohen R: Novel chemiluminescence-inducing cocktails. II. Measurement of the anti-oxidant capacity of vitamins, thiols, body fluids, alcoholic beverages and edible oils. Immunopharmacology 2004;12:305–320.
28.
Martin LD, Rochelle LG, Fischer BM, Krunkosky TM, Adler KN: Airway epithelium as an effector of inflammation: molecular regulation of secondary mediators. Eur Respir J 199;10:2139–2146.
29.
Cromwell O, Hamid Q, Conigan C, Barkans J, Ueng Q, Collins P: Expression and generation of interleukin-8, IL-6 and granulocyte-macrophage colonary-stimulating factor by bronchial epithelial cells and enhancement by IL-1 beta and tumor necrosis factor-alpha. Immunology 1992;7:330–337.
30.
Adler K, Fischer B, Wright D, Cohn L, Becker S: Interaction between respiratory epithelial cells and cytokines: relationships to lung inflammation. Ann NY Acad Sci 1994;725:128–145.
31.
Christman JW, Sadikot RT, Blackwell TS: The role of nuclear factor-kappa B in pulmonary diseases. Chest 2000;117:1482–1487.
32.
Lehrer RI, Ganz T, Selsted ME, Babior BM, Curnutte JT: Neutrophils and host defense. Ann Int Med 1988;19:127–142.
33.
Venge P, Rak S, Steinholtz L, Hakansson L, Lindblad G: Neutrophil function in chronic bronchitis. Eur Respir J 1991;4:536–543.
34.
Müns G, Rubinstein I, Singer P: Phagocytosis and oxidative burst of granulocytes in the upper respiratory tract in chronic and acute inflammation. J Otolaryngol 1995;24:105–110.
35.
Levine SJ: Bronchial epithelial cell-cytokine interactions in airway inflammation. J Investig Med 1995;43:241–249.
36.
Ichinose M, Sugiura H, Yamagata S, Koarai A, Shirato K: Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. Am J Respir Crit Care Med 2000;162:701–706.
37.
Kanazawa H, Shiraishi S, Hirata K, Yoshikawa J: Imbalance between levels of nitrogen oxides and peroxynitrite inhibitory activity in chronic obstructive pulmonary disease. Thorax 2003;58:106–109.
38.
Schmidt HHHW, Seifert R, Bohme E: Formation and release of nitric oxide from human neutrophils and HL-60 cells induced by a chemotactic peptide, platelet activating factor and leukotriene B4. FEBS Lett 1989;244:357–360.
39.
Stolarek R, Kula P, Kurmanowska Z, Nowak D: Effect of various agonists on nitric oxide generation by human polymorphonuclear leukocytes. Int J Clin Lab Res 1998;28:104–109.
40.
Radi R, Cosgrove TP, Beckman JS, Freeman BA: Peroxynitrite-induced luminol chemiluminescence. Biochem J 1993;290:51–57.
41.
Beckman JS, Beckman TW, Chen J, Marhsall PA, Freeman BA: Apparent hydroxyl radical production by peroxynitrite: implication for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87:1620–1624.
42.
Hogg N, Darley-Usman VM, Wilson MT, Moncada S: Production of hydroxyl radicals from simultaneous generation of superoxide and nitric oxide. Biochem J 1992;28:419–424.
43.
Vachier I, Chanez P, Le Douceu C, Dampon M, Descomps B, Godard P: Enhancement of reactive oxygen species formation in stable and unstable asthmatic patients. Eur Resp J 1994;7:1585–1592.
44.
National Research Council (USA): Hydrogen Sulfide Subcommittee on Hydrogen Sulfide. Baltimore, University Park Press, 1979.
45.
Tossell JA: Theoretical studies on possible sulfur oxides with +2 oxidation states in aqueous solution. Chem Geol 1997;141:93–103.
46.
Li L, Bhatia M, Zhu YZ, Zhu YC, Ramnath RD, Wang ZJ, Anuar FBM, Whiteman M, Sulto-Tellez M, Moore PK: Hydroen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse. FASEB 2005;19:1196–1198.
47.
Stipanuk MH, Beck PW: Characterization of the enzymic capacity for cysteine desulphydration in liver and kidney of the rat. Biochem J 1982;206:267–277.
48.
Griffith OW: Mammalian sulfur aminoacid metabolism: an overview. Meth Enzymol 1987;143:366–376.
49.
Rosenberg M, Septon I, Eli I, Bar-Ness R, Gelernter I, Brenner S, Gabbay J: Halitosis measurement by an industrial sulphide monitor. J Periodontol 1991;62:487–489.
50.
Beauchamp RO Jr, Bus JS, Popp JA, Boreiko CJ, Andjelkovich DA: A critical review of the literature on hydrogen sulfide toxicity. Crit Rev Toxicol 1984;13:25–97.
51.
Cali C, Taillades G, Pradel A, Ribes M: Determination of sulfur species using a glassy-crystalline chalcogenide membrane. Sens Actuators B 2001;76:560–564.
52.
Abe K, Kimura H: The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci 1996;16:1066–1071.
53.
Li L, Bhatia M, Moore PK: Hydrogen sulphide – a novel mediator of inflammation? Curr Opin Pharmacol 2006;6:125–129.
54.
Geng B, Chang L, Pan C, Qi Y, Lhao J, Pang Y, Du J, Tang C: Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol. Biochem Biophys Res Commun 2004;318:756–763.
55.
Zhao W, Zhang J, Lu Y, Wang R: The vasorelaxant effect of H2S as a novel endogenous gaseous KATP channel opener. EMBO J 2001;20:6008–6016.
56.
Moore PK, Bhatia M, Moochhala S: Hydrogen sulfide: from the swell of the past to the mediator of the future? Trends Pharmacol Sci 2003;24:609–611.
57.
Carreras MC, Pargament GA, Cotz SD, Poderoso JJ, Boveris A: Kinetics of nitric oxide and hydrogen peroxide production and formation of peroxynitrite during the respiratory burst of human neutrophils. FEBS Lett 1994;341:65–68.
58.
Forslund T, Sundqvist T: Nitric oxide regulates the chemiluminescence from stimulated human neutrophils. APMIS 1995;103:813–817.
59.
Wang JF, Komarow P, Sies H, De Groot H: Contribution of nitric oxide synthase to luminol-dependent chemiluminescence generated by phorbol-ester activated kupfer cells. Biochem J 1991;279:311–314.
60.
World Health Organization: Hydrogen sulfide: Human Health Aspects. Concise International Chemical Assessment Document 53. Geneva, World Health Organization, 2003.
61.
Hull FB: Atmospheric sulfur and its links to the biota. Brookhaven Symp Biol 1973;30:159–181.
62.
World Health Organization: Hydrogen Sulfides. Environmental Health Criteria 19. Geneva, World Health Organization, 1981.
63.
Hunisch GW: Stoichiometry of the reaction of sulfites with hydrogen sulfide ion. Inorg Chem 1977;16:1411–1413.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.